ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$16.94 USD
-0.08 (-0.47%)
Updated May 1, 2024 04:00 PM ET
After-Market: $16.92 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ALXO 16.94 -0.08(-0.47%)
Will ALXO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALXO
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
Other News for ALXO
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
ALX Oncology announces initiation of Phase 2 trial in patients with HPVOC
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
ALX Oncology: Trying To Justify The Hype
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session